Beximco Pharmaceuticals (DHA:BXPHARMA) Cyclically Adjusted Book per Share: BDT97.12 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:BXPHARMA Beximco Pharmaceuticals PLC DHA:BXPHARMA
94 GF Score
Price BDT150.90
GF Value BDT128.18
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Beximco Pharmaceuticals Cyclically Adjusted Book per Share?

Beximco Pharmaceuticals DHA:BXPHARMA +2.58% 94 Cyclically Adjusted Book per Share is BDT97.12 as of Mar. 2026. GuruFocus rates DHA:BXPHARMA with a GF Score™ of 94/100 and a GF Value™ of BDT128.18 (Modestly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

Beximco Pharmaceuticals's adjusted book value per share for the three months ended in Mar. 2026 was BDT134.604. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is BDT97.12 for the trailing ten years ended in Mar. 2026.

During the past 3 years, the average Cyclically Adjusted Book Growth Rate was 5.70% per year. During the past 5 years, the average Cyclically Adjusted Book Growth Rate was 0.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Book Growth Rate of Beximco Pharmaceuticals was 5.70% per year. The lowest was -7.70% per year. And the median was -4.60% per year.

As of today (2026-08-02), Beximco Pharmaceuticals's current stock price is BDT150.90. Beximco Pharmaceuticals's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was BDT97.12. Beximco Pharmaceuticals's Cyclically Adjusted PB Ratio of today is 1.55.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Beximco Pharmaceuticals was 3.22. The lowest was 0.59. And the median was 1.27.


Beximco Pharmaceuticals  (DHA:BXPHARMA) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Beximco Pharmaceuticals's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=150.90/97.12
=1.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PB Ratio of Beximco Pharmaceuticals was 3.22. The lowest was 0.59. And the median was 1.27.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


Beximco Pharmaceuticals Cyclically Adjusted Book per Share Related Terms


Beximco Pharmaceuticals Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for Beximco Pharmaceuticals's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beximco Pharmaceuticals Cyclically Adjusted Book per Share Chart

Beximco Pharmaceuticals Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 80.67 76.80 76.77 83.77 90.73

Beximco Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 90.73 92.91 94.34 97.12

DHA:BXPHARMA vs ZTS, UTHR, VTRS: Cyclically Adjusted Book per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beximco Pharmaceuticals Cyclically Adjusted PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Beximco Pharmaceuticals's Cyclically Adjusted PB Ratio falls into.


DHA:BXPHARMA
94GF Score
Beximco Pharmaceuticals PLC DHA:BXPHARMA
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beximco Pharmaceuticals Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Beximco Pharmaceuticals's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=134.604/330.2130*330.2130
=134.604

Current CPI (Mar. 2026) = 330.2130.

Beximco Pharmaceuticals Quarterly Data

Book Value per Share CPI Adj_Book
201606 54.274 241.018 74.360
201609 52.787 241.428 72.199
201612 53.698 241.432 73.444
201703 54.872 243.801 74.321
201706 56.202 244.955 75.763
201709 57.596 246.819 77.056
201712 57.970 246.524 77.649
201803 59.326 249.554 78.501
201806 60.707 251.989 79.552
201809 62.352 252.439 81.562
201812 62.860 251.233 82.621
201903 64.538 254.202 83.836
201906 66.325 256.143 85.504
201909 68.262 256.759 87.790
201912 68.783 256.974 88.387
202003 70.801 258.115 90.577
202006 72.841 257.797 93.302
202009 75.255 260.280 95.475
202012 76.447 260.474 96.915
202103 79.732 264.877 99.399
202106 83.007 271.696 100.885
202109 86.311 274.310 103.901
202112 86.655 278.802 102.634
202203 89.129 287.504 102.369
202206 91.010 296.311 101.423
202209 94.247 296.808 104.854
202212 93.522 296.797 104.052
202303 95.654 301.836 104.647
202306 97.914 305.109 105.970
202309 101.396 307.789 108.783
202312 101.110 306.746 108.845
202403 104.169 312.332 110.133
202406 107.484 314.175 112.971
202409 111.252 315.301 116.514
202412 111.354 315.605 116.508
202503 0.000 319.799 0.000
202506 119.044 322.561 121.868
202509 124.342 324.800 126.414
202512 129.627 324.054 132.091
202603 134.604 330.213 134.604

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of BDT97.12 mean?
Beximco Pharmaceuticals (DHA:BXPHARMA) has a Cyclically Adjusted Book per Share of BDT97.12 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Beximco Pharmaceuticals and its competitors.
Is Beximco Pharmaceuticals' Cyclically Adjusted Book per Share too high?
Beximco Pharmaceuticals' current Cyclically Adjusted Book per Share is BDT97.12. Overall, Beximco Pharmaceuticals has a GF Score™ of 94/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' Cyclically Adjusted Book per Share compare to ZTS and UTHR?
Beximco Pharmaceuticals' Cyclically Adjusted Book per Share of BDT97.12 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Book per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on Beximco Pharmaceuticals and its competitors. Beximco Pharmaceuticals's current Cyclically Adjusted Book per Share is BDT97.12. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Beximco Pharmaceuticals (DHA:BXPHARMA) is currently considered Modestly Overvalued. The stock's GF Value™ is BDT128.18, compared to a current price of BDT150.90 — trading 17.7% above its estimated fair value. The current Cyclically Adjusted Book per Share is BDT97.12. Beximco Pharmaceuticals' overall GF Score™ is 94/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For Beximco Pharmaceuticals (DHA:BXPHARMA), the current Cyclically Adjusted Book per Share is BDT97.12 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beximco Pharmaceuticals (DHA:BXPHARMA) Overvalued in 2026?

Based on GuruFocus' analysis, Beximco Pharmaceuticals stock appears to be overvalued. The current stock price of BDT150.90 is trading 17.7% above its estimated GF Value™ of BDT128.18. GuruFocus considers Beximco Pharmaceuticals to be Modestly Overvalued.

Key valuation signals for DHA:BXPHARMA:

  • Cyclically Adjusted Book per Share: BDT97.12
  • GF Value™: BDT128.18 vs. price of BDT150.90 (17.7% above fair value)
  • GF Score™: 94/100 with 5 warning signs

No single metric tells the full story. See the DHA:BXPHARMA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Beximco Pharmaceuticals Business Description

Other Exchanges BXP:UKR2WA:Germany
Address 19 Dhanmondi, Road No. 7, Dhaka, BGD, 1205
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
94GF Score

Get the complete analysis for DHA:BXPHARMA

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT150.90
Price
BDT128.18
GF Value